The Leukaemia Research Group is headed by Professor Øystein Bruserud.
The research has a major focus on the hematological malignancy acute myeloid leukaemia (AML); an aggressive disease that can be cured only by intensive chemotherapy eventually in combination with stem cell transplantation. Our main research areas are (i) preleukaemic disorders, (ii) biological and functional characterization of primary human AML cells and their interactions with stromal elements and (iii) experimental studies of efficiency and toxicity (especially immunotoxicity) of both new targeted therapies and already established therapeutic strategies in human AML.
Ongoing research in our laboratory includes:
• Identification of patient subsets based on biological and functional characteristics (such as proteomic and metabolomic characteristics, intracellular signaling pathways) as well as pharmacological in vitro studies.
• Immunological studies of patients receiving conventional chemotherapy as well as autologous and allogeneic stem cell transplantation.
• Translational research in allogeneic stem cell transplantation, including studies of healthy donors and characterization of stem cell grafts.
• Phase I/II clinical studies of disease-stabilizing treatment in AML patients unfit for intensive therapy.
Øystein Bruserud receives research prize from Helse Vest for his achievments in the field of AML research
Through his work, Bruserud has contributed considerably in the field of hematological research. His commitment has created the foundation for research activity on AML, on a high national and international level, in the Helse Vest region.
More information can be found at this link